1.Study on the new workflow of PIVAS based on intelligent auxiliary devices
Haiwen DING ; Sheng LIU ; Zhaolin CHEN ; Liqin TANG ; Tong TONG
China Pharmacy 2026;37(1):99-104
OBJECTIVE To build a new workflow of pharmacy intravenous admixture services (PIVAS), effectively connect intelligent equipment, and promote the intelligent development of PIVAS. METHODS Based on intelligent auxiliary equipment, PIVAS workflow was optimized, and a process-oriented model was established. This model integrated intelligent prescription review (automatic prescription review+manual intervention mode), intelligent labeling, intelligent allocation, intelligent sorting, and finished infusion quality inspection system. Furthermore, an assessment was conducted to examine unreasonable medical order rate of intelligent prescription review, the working efficiency and error rate of intelligent labeling machine and intelligent sorting machine, and the dispensing efficiency and accuracy of intelligent dispensing robot. RESULTS Under the intelligent prescription review mode, the rate of unreasonable medical orders decreased from 0.157% to 0.050% (P<0.05); automatic labeling efficiency reached 21.7 sheets/min, surpassing the manual labeling efficiency of 13.8 sheets/min (P<0.05), and the daily labeling error rate decreased from 6.1‰ to 2.5‰ (P<0.05). Simultaneously operating two dispensing robots significantly improved the efficiency of batch dispensing and reduced the residual amount of liquid medicine (P<0.05); additionally, a quality testing system for finished infusion was established, involving appearance, Tyndall effect, insoluble particles, turbidity, absorbance, pH and osmotic pressure, to ensure the quality of finished infusion and reduce the risk of infusion. CONCLUSIONS The new process of PIVAS connected with intelligent devices in our hospital can improve work efficiency, reduce dispensing errors, ensure the quality of finished infusion, and improve the level of pharmaceutical care.
2.Transfusion-transmitted hepatitis E
Baixun LI ; Tianxu LIU ; Liqin HUANG ; Yingnan DANG ; Lin WANG
Chinese Journal of Blood Transfusion 2025;38(1):38-42
Hepatitis E is an acute and self-limiting viral hepatitis caused by the hepatitis E virus (HEV). It has a higher mortality rate among immunosuppressed patients and pregnant women infected with HEV. Although HEV infections in humans are mostly caused by contaminated water or food worldwide, the incidence of transfusion-transmitted hepatitis E is continuously rising. Additionally, the prevalence of serum anti-HEV IgG in the blood donors in China is at a relatively high level, making it worth considering screening blood donors for HEV. This article briefly reviews the globally reported cases of transfusion-transmitted hepatitis E and the HEV screening strategies for blood donations.
3.Quantitative analysis of 10 components in Compound Dihuang oral solution by UPLC-MS/MS
Hongxia LIU ; Yanwen SUN ; Fei HAN ; Yan ZHOU ; Huajun SUN ; Liqin DING
Journal of Pharmaceutical Practice and Service 2025;43(8):390-394
Objective To develop an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to simultaneously determine 10 main components, including berberine, phellodendrine, specnuezhenide, mangiferin, loganin, paeoniflorin, geniposide, baicalin, and acteoside in Compound Dihuang oral solution. Methods An UPLC-MS/MS method was established with an ACQUITY UPLC BEH-C18 (2.1 mm×100 mm, 1.7 μm)column and mobile phase of 0.1% formic water(A)-methanol solution(B) in a gradient elution manner. The flow rate of mobile phase was 0.2 ml/min.The temperature of column was 30℃. The injection volume was 2 μl. The MS detection was in MRM mode. Results 10 components in Compound Dihuang oral solution had a good linear relationship within their concentration range,and the precision, repeatability, stability and recovery met the requirements. The contents of berberine, phellodendrine, specnuezhenide, mangiferin, loganin, paeoniflorin, geniposide, baicalin, and acteoside in 7 batches of samples were (89.7-95.6) μg/ml, (164.0-177.7) μg/ml, (540.0-610.0) μg/ml, (408.7-429.0) μg/ml, (726.0-825.0) μg/ml, (503.7-572.0) μg/ml, (
4.Increasing trends of hyperglycemia and diabetes in treatment-naive people living with HIV in Shenzhen from 2013 to 2019: An emerging health concern.
Liqin SUN ; Haipeng ZHU ; Man RAO ; Fang ZHAO ; Yang ZHOU ; Lukun ZHANG ; Xia SHI ; Jianwei WU ; Yun HE ; Hongzhou LU ; Jiaye LIU
Chinese Medical Journal 2025;138(16):2043-2045
5.Transparency of clinical practice guidelines: A mixed methods research.
Xinyi WANG ; Youlin LONG ; Tengyue HU ; Zixin YANG ; Liqin LIU ; Liu YANG ; Yifan CHENG ; Ran GU ; Yanjiao SHEN ; Nan YANG ; Jin HUANG ; Yaolong CHEN ; Liang DU
Chinese Medical Journal 2025;138(15):1882-1884
6.Functional aptamer evolution-enabled elucidation of a melanoma migration-related bioactive epitope.
Hong XUAN ; Siqi BIAN ; Qinguo LIU ; Jun LI ; Shaojin LI ; Sharpkate SHAKER ; Haiyan CAO ; Tongxuan WEI ; Panzhu YAO ; Yifan CHEN ; Xiyang LIU ; Ruidong XUE ; Youbo ZHANG ; Liqin ZHANG
Acta Pharmaceutica Sinica B 2025;15(6):3196-3209
Metastasis is the leading cause of death from cutaneous melanoma. Identifying metastasis-related targets and developing corresponding therapeutic strategies are major areas of focus. While functional genomics strategies provide powerful tools for target discovery, investigations at the protein level can directly decode the bioactive epitopes on functional proteins. Aptamers present a promising avenue as they can explore membrane proteomes and have the potential to interfere with cell function. Herein, we developed a target and epitope discovery platform, termed functional aptamer evolution-enabled target identification (FAETI), by integrating affinity aptamer acquisition with phenotype screening and target protein identification. Utilizing the aptamer XH3C, which was screened for its migration-inhibitory function, we identified the Chondroitin Sulfate Proteoglycan 4 (CSPG4), as a potential target involved in melanoma migration. Further evidence demonstrated that XH3C induces cytoskeletal rearrangement by blocking the interaction between the bioactive epitope of CSPG4 and integrin α4. Taken together, our study demonstrates the robustness of aptamer-based molecular tools for target and epitope discovery. Additionally, XH3C is an affinity and functional molecule that selectively binds to a unique epitope on CSPG4, enabling the development of innovative therapeutic strategies.
7.Fibrinogen-tau Aggregates Exacerbate Tau Pathology and Memory Deficits in Alzheimer's Disease Model Mice.
Tingting WEN ; Lanxia MENG ; Han LIU ; Qian ZHANG ; Lijun DAI ; Liqin HUANG ; Liang DAN ; Kedong ZHU ; Jiaying LUO ; Zhaohui ZHANG
Neuroscience Bulletin 2025;41(7):1246-1260
Vascular damage plays a significant role in the onset and progression of Alzheimer's disease (AD). However, the precise molecular mechanisms underlying the induction of neuronal injury by vascular damage remain unclear. The present study aimed to examine the impact of fibrinogen (Fg) on tau pathology. The results showed that Fg deposits in the brains of tau P301S transgenic mice interact with tau, enhancing the cytotoxicity of pathological tau aggregates and promoting tau phosphorylation and aggregation. Notably, Fg-modified tau fibrils caused enhanced neuronal apoptosis and synaptic damage compared to unmodified fibrils. Furthermore, intrahippocampal injection of Fg-modified tau fibrils worsened the tau pathology, neuroinflammation, synaptic damage, neuronal apoptosis, and cognitive dysfunction in tau P301S mice compared to controls. The present study provides compelling evidence linking Fg and tau, thereby connecting cerebrovascular damage to tau pathology in AD. Consequently, inhibiting Fg-mediated tau pathology could potentially impede the progression of AD.
Animals
;
tau Proteins/metabolism*
;
Alzheimer Disease/metabolism*
;
Fibrinogen/metabolism*
;
Mice, Transgenic
;
Mice
;
Disease Models, Animal
;
Memory Disorders/metabolism*
;
Male
;
Mice, Inbred C57BL
;
Brain/metabolism*
;
Hippocampus/metabolism*
;
Protein Aggregation, Pathological/metabolism*
;
Apoptosis
;
Phosphorylation
8.Construction and application of 5G UAV intelligent airport platform for blood transportation
Li NING ; Litao WU ; Jinhong LIU ; Sheng ZHANG ; Tailong TAN ; Liqin HUANG ; Xuqun WU
Chinese Journal of Blood Transfusion 2025;38(10):1389-1394
Objective: To construct a 5G unmanned aerial vehicle (UAV) airport platform for blood transportation and explore its feasibility and advantages within the blood emergency support system. Methods: Based on 5G high-speed network transmission technology, a UAV management system was designed to achieve a closed-loop management of the entire transportation process, including blood distribution, route information, flight status, emergency dispatch, hospital reception, real-time temperature monitoring, and video surveillance. Integrated with an open UAV airport, the first "5G UAV Blood Transportation Intelligent Airport Platform" was established. Results: At present, the platform has settled in 2 sets of UAV systems, established 17 routes, and carried out regular UAV blood transportation services for 15 hospitals. From January 1, 2024 to June 30, 2025, a total of 12 134 sorties were completed, with a total transported blood weight of 7 692.38 kg, including 25 500 units of red blood cells, 3 824.5 units of platelets, 1 350 370 mL of plasma, and 10 810 units of cryoprecipitate. Compared to land transportation, UAV delivery saved an average of 46.8 minutes during rush hours (maximum: 89.3 minutes) and an average of 32.3 minutes during non-rush hours (maximum: 59.1 minutes). In terms of the quality of UAV blood transportation, the temperature of suspended red blood cells was between 4 and 8℃, that of platelets was between 20 and 24℃, and that of plasma was below 0℃. No damage has occurred so far. Conclusion: The UAV blood transportation platform can stably provide blood delivery services during both routine and emergency conditions, ensuring timely blood delivery and stable blood quality.
9.Design,synthesis and antiplatelet aggregation activity of 3-acetyl-7-hydroxycoumarin derivatives
Feiyang SHANG ; Chengbo LIU ; Hongzhou TAN ; Bing HE ; Liqin HE
Journal of China Pharmaceutical University 2024;55(3):367-374
In order to search for coumarin-based anti-platelet aggregation compounds with high efficacy and good druggability,twenty-five 3-acetyl-7-hydroxy-coumarin oxime derivatives(6a-6y)were synthesized via Vilsmeier-Haack reaction,Knoevenagel reaction,Williamson reaction,electrophilic substitution reaction and oximation reaction from resorcinol.Their structures were confirmed by HRMS and 1H NMR spectra.The anti-platelet aggregation activity of the target compounds was evaluated using Born's turbidimetric method.The results revealed that most of them could significantly inhibit platelet aggregation induced by adenosine diphosphate(ADP),collagen,arachidonic acid(AA)and thrombin.Among them,the target compounds 6a and 6b not only had strong inhibitory activity on platelet aggregation induced by the four inducers,but also exhibited good water solubility(3.46 mg/mL and 3.85 mg/mL,respectively)and lipid-water partition coefficient(2.56 and 2.85,respectively)and were expected to become a preclinical candidate compound with multi-target action against platelet aggregation.
10.Application and Research Progress of 225 Ac in Tumor Targeted Treatment
Journal of Sun Yat-sen University(Medical Sciences) 2024;45(4):503-510
225Ac has high linear energy transfer,suitable half-life,short particle range,and good coordination abili-ty,making it one of the promising alpha emitters in targeted radioisotope therapy for tumors,and it has significant research value.This article briefly introduces the physical and chemical properties of 225Ac,as well as common chelating agents(prostate-specific membrane antigen,octreotide,nano-carriers,etc.).It reviews the applications of targeted drugs la-beled with 225Ac in tumors,based on peptides or small molecules as targeting agents,monoclonal antibodies or proteins as targeting molecules,and nano-carriers.It also analyzes the value of its application in therapy,summarizes the methods of labeling with 225Ac and the selection of suitable chelating agents,improvements in targeting specificity,and toxicity side ef-fects.Furthermore,it looks forward to the localization of 225Ac production to meet future clinical needs,in order to provide reference for the subsequent development of 225Ac-labeled drugs.

Result Analysis
Print
Save
E-mail